Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2. (2022)
Attributed to:
Development of LRRK2 PROTAC degraders as chemical probes and potential lead compounds for the treatment of Parkinson's disease
funded by
Horizon Europe Guarantee
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1021/jacs.2c05499
PubMed Identifier: 36007011
Publication URI: http://europepmc.org/abstract/MED/36007011
Type: Journal Article/Review
Volume: 144
Parent Publication: Journal of the American Chemical Society
Issue: 37
ISSN: 0002-7863